Regnase-1 overexpression as a therapeutic approach of Marfan syndrome.
Marfan syndrome
adeno-associated virus vector
aortic aneurysm
gene therapy
mouse model
regnase-1
vascular system
Journal
Molecular therapy. Methods & clinical development
ISSN: 2329-0501
Titre abrégé: Mol Ther Methods Clin Dev
Pays: United States
ID NLM: 101624857
Informations de publication
Date de publication:
14 Mar 2024
14 Mar 2024
Historique:
received:
31
05
2023
accepted:
16
11
2023
medline:
5
1
2024
pubmed:
5
1
2024
entrez:
5
1
2024
Statut:
epublish
Résumé
Rupture or dissection of thoracic aortic aneurysms is still the leading cause of death for patients diagnosed with Marfan syndrome. Inflammation and matrix digestion regulated by matrix metalloproteases (MMPs) play a major role in the pathological remodeling of the aortic media. Regnase-1 is an endoribonuclease shown to cleave the mRNA of proinflammatory cytokines, such as interleukin-6. Considering the major anti-inflammatory effects of regnase-1, here, we aimed to determine whether adeno-associated virus (AAV)-mediated vascular overexpression of the protein could provide protection from the development and progression of aortic aneurysms in Marfan syndrome. The overexpression of regnase-1 resulted in a marked decrease in inflammatory parameters and elastin degradation in aortic smooth muscle cells
Identifiants
pubmed: 38178915
doi: 10.1016/j.omtm.2023.101163
pii: S2329-0501(23)00202-4
pmc: PMC10762926
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101163Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
T.B. and C.K. have previously filed a patent application on the polymer coating for the vascular targeting of AAVs. The other authors declare no competing interests.